Magnesium
As of the edition of 20 October 2026, Magnesium is a small molecule: marketed, first approved in 1934 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Aminosyn 3.5% M
- First approved
- 31 August 1934 (CH)
- Approvals on record
- 243 in 5 regions
- Holder of the most recent approval
- Baxter Healthcare; 26 holders in all
- Registered trials
- 54, 7 stopped early
- Disease areas
- Nervous system; Heart and blood vessels; Cancer; Bones, joints and muscles; Mental health; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 17 | 10 | 3 | 2 |
| Phase 1 | 4 | 2 | 0 | 1 |
| Phase 2 | 13 | 6 | 1 | 2 |
| Phase 3 | 9 | 6 | 1 | 2 |
| Phase 4 | 11 | 10 | 1 | 0 |
| All trials | 54 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| B. Braun Medical | Applicant | 1980 to now |
| Alcon | Applicant | 1980 to now |
| Pfizer | Acquired holder and Later holder | 1983 to now |
| Bayer | Later holder | 1984 to now |
| Astellas | Applicant | 1986 to now |
| Baxter Healthcare | Later holder | 1990 to now |
| Abbott | Later holder | 1994 to now |
| Johnson & Johnson | Later holder | 1994 to now |
| Fresenius Kabi | Acquired holder | 2013 to now |
| Nihon Pharmaceutical | Applicant | 2021 to now |